2022
Multimodal analysis suggests differential immuno-metabolic crosstalk in lung squamous cell carcinoma and adenocarcinoma
Leitner BP, Givechian KB, Ospanova S, Beisenbayeva A, Politi K, Perry RJ. Multimodal analysis suggests differential immuno-metabolic crosstalk in lung squamous cell carcinoma and adenocarcinoma. Npj Precision Oncology 2022, 6: 8. PMID: 35087143, PMCID: PMC8795406, DOI: 10.1038/s41698-021-00248-2.Peer-Reviewed Original ResearchNon-small cell lung cancerLung squamous cell carcinomaBody mass indexSquamous cell carcinomaLung adenocarcinomaHigher glucose uptakeVisceral adiposityVisceral fatCell carcinomaLung cancerGlucose uptakeTreatment of NSCLCHigher body mass indexTumor-infiltrating T cellsImmune checkpoint inhibitionCell lung cancerHigh visceral fatPET/CT imagingTumors of patientsPrecision therapy approachesTumor glucose uptakePrecision medicine approachLUSC tumorsPrognostic gene expressionAdjunct therapy
2019
Deep Learning Implicitly Handles Tissue Specific Phenomena to Predict Tumor DNA Accessibility and Immune Activity
Wnuk K, Sudol J, Givechian K, Soon-Shiong P, Rabizadeh S, Szeto C, Vaske C. Deep Learning Implicitly Handles Tissue Specific Phenomena to Predict Tumor DNA Accessibility and Immune Activity. IScience 2019, 20: 119-136. PMID: 31563852, PMCID: PMC6823659, DOI: 10.1016/j.isci.2019.09.018.Peer-Reviewed Original ResearchDNA accessibilityChromatin stateOpen chromatin stateChromatin regulationSpecific tissue typesPromoter-flanking regionAccessibility landscapeCancer Genome AtlasTranscriptional eventsTissue-specific phenomenonDNA sequencesGenome AtlasTissue typesImmune pathwaysPromoterTumor progressionAccessibility patternsLung adenocarcinomaNew toolKey dynamic featuresTumor typesPathwayRegulationImmune activitySequenceAn immunogenic NSCLC microenvironment is associated with favorable survival in lung adenocarcinoma
Givechian KB, Garner C, Benz S, Song B, Rabizadeh S, Soon-Shiong P. An immunogenic NSCLC microenvironment is associated with favorable survival in lung adenocarcinoma. Oncotarget 2019, 10: 1840-1849. PMID: 30956762, PMCID: PMC6442995, DOI: 10.18632/oncotarget.26748.Peer-Reviewed Original ResearchLung squamous cell carcinomaNon-small cell lung cancerSquamous cell carcinomaLung adenocarcinomaTumor microenvironmentCell carcinomaLung cancerFavorable patient survivalImmune-excluded tumorsCell lung cancerInflamed tumor microenvironmentImmune checkpoint marker expressionLung adenocarcinoma subtypesMajor NSCLC subtypesAnti-tumor immunogenicityImmunological mechanismsFavorable survivalPrognostic effectAdenocarcinoma subtypePatient survivalSurvival outcomesNSCLC subtypesImmune cellsNSCLC microenvironmentLUSC samples